Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist with a 5-day half-life that reaches steady-state concentrations after four to five weeks of consistent dosing
GLP-1RAs disrupt this inflammatory cascade by diminishing adipose tissue macrophage infiltration, enhancing insulin sensitivity via reduced inflammatory signaling, and safeguarding pancreatic -cells from inflammatory harm (Pang et al
This slow-down in digestion can lead to more gastrointestinal side effects, such as nausea, diarrhea, constipation, and, of course, burping
Even as the FDA has raised dosing and other concerns with compounded semaglutide and tirzepatide, it has allowed the compounded medications to be manufactured during the drug shortages
Limitations of the current study, which should also be considered for future studies, include the post hoc nature of the analysis, meaning that assessed outcomes were not prespecified in the original study protocol